Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2021 - 2026)
Neuphoria Therapeutics (NEUP) reported Total Non-Current Liabilities of $4.4 million for Q1 2026, up 54.19% year-over-year from $2.8 million in Q1 2025, and up 4.22% on a QoQ basis from $4.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 6 years of Total Non-Current Liabilities data on file, last reported at $4.4 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 54.19% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 54.19% YoY) and the FY2025 annual result came in at $8.4 million, up 53.02% from the prior year.
- Total Non-Current Liabilities advanced to $4.4 million in Q1 2026 per NEUP's latest filing, from $4.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $8.4 million in Q2 2025 and bottomed at $2.8 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $4.4 million (2024), against an average of $5.0 million.
- The widest annual swing landed in 2025, when Total Non-Current Liabilities retreated 5.26%; it then jumped 54.19% in 2026.
- Tracing NEUP's Total Non-Current Liabilities over 5 years: stood at $3.6 million in 2022, then grew by 5.99% to $3.8 million in 2023, then advanced by 15.4% to $4.4 million in 2024, then slipped by 5.26% to $4.2 million in 2025, then grew by 4.22% to $4.4 million in 2026.
- Per Business Quant, the three latest NEUP Total Non-Current Liabilities figures stand at $4.4 million (Q1 2026), $4.2 million (Q4 2025), and $6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 5.72 Mn |
| Sep 30, 2025 | 6.74 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 3.84 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 9.57 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Jun 30, 2022 | 3.61 Mn |
| Dec 31, 2021 | 3.09 Mn |
| Jun 30, 2021 | 3.32 Mn |